EBMT 2023 | The challenge of relapse in transplant-eligible & transplant-ineligible patients with BDPCN
Marco Herling
• 25 Apr 2023
Marco Herling, MD, University of Leipzig, Leipzig, Germany, comments on the challenge of dealing with relapse in blastic plasmacytoid dendritic cell neoplasm (BPDCN) after stem cell transplantation in transplant-eligible patients and following treatment with tagraxofusp in transplant-ineligible patients, highlighting strategies to prevent relapse. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
